Notably, targeting the MAPK pathway by the BRAF inhibitor, vemurafenib, or the MEK inhibitor, dabrafenib, have been approved by the FDA for V600E mutant BRAF-harboring melanomas. The gene discussed is BRAF; the disease is melanoma.